{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:15:31Z","timestamp":1771640131539,"version":"3.50.1"},"reference-count":60,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Colon Rectal Surg"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The landscape of management of ulcerative colitis, a type of inflammatory bowel disease, continues to change with advancement in pharmaceutical options as well as clinical treatment targets. Ulcerative colitis primarily involves the superficial layers of the large bowel, and cause active inflammation that can affect the colon from the rectum to the cecum in a relapsing and a remitting course. In this review, we provide evidence-based guidance on the selection of appropriate medical therapies based on individual patient and disease characteristics, with a focus on biologics and small molecules. We also review the role of surgery and management of acute severe ulcerative colitis.<\/jats:p>","DOI":"10.1055\/s-0042-1758048","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T13:19:51Z","timestamp":1670678391000},"page":"428-436","source":"Crossref","is-referenced-by-count":10,"title":["Medical Treatment Options for Ulcerative Colitis"],"prefix":"10.1055","volume":"35","author":[{"given":"Joseph","family":"Sleiman","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehak","family":"Bassi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Saint Peter's University Hospital, Rutgers University, New Brunswick, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Tsipotis","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Augusta University, Augusta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Charabaty","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.cgh.2016.10.039","article-title":"Incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010","volume":"15","author":"R Shivashankar","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/apt.13307","article-title":"Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients","volume":"42","author":"E Safroneeva","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"05","key":"ref3","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"D Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"13","key":"ref4","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"B E Sands","year":"2019","journal-title":"N Engl J Med"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.gastro.2016.10.005","article-title":"Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases","volume":"152","author":"J Panes","year":"2017","journal-title":"Gastroenterology"},{"issue":"09","key":"ref6","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"L Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","article-title":"Defining disease severity in inflammatory bowel diseases: current and future directions","volume":"14","author":"L Peyrin-Biroulet","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"D T Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/j.gastro.2015.05.036","article-title":"Ulcerative colitis care pathway","volume":"149","author":"T Dassopoulos","year":"2015","journal-title":"Gastroenterology"},{"issue":"08","key":"ref10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40265-015-0396-8","article-title":"Budesonide MMX(\u00ae): a review of its use in patients with mild to moderate ulcerative colitis","volume":"75","author":"S M Hoy","year":"2015","journal-title":"Drugs"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","article-title":"Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease","volume":"160","author":"U Mahadevan","year":"2021","journal-title":"Gastroenterology"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2036.2009.04023.x","article-title":"Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis","volume":"30","author":"J P Gisbert","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"08","key":"ref13","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jama.2019.0709","article-title":"Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease","volume":"321","author":"G J Walker","year":"2019","journal-title":"JAMA"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0016-5085(00)70140-5","article-title":"Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease","volume":"118","author":"M C Dubinsky","year":"2000","journal-title":"Gastroenterology"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1053\/j.gastro.2013.09.035","article-title":"Lymphoma: the b\u00eate noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease","volume":"145","author":"L Beaugerie","year":"2013","journal-title":"Gastroenterology"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/gutjnl-2014-307126","article-title":"Systematic review: monotherapy with antitumour necrosis factor \u03b1 agents versus combination therapy with an immunosuppressive for IBD","volume":"63","author":"P S Dulai","year":"2014","journal-title":"Gut"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/apt.13466","article-title":"Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"43","author":"A Bourrier","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"W J Sandborn","year":"2014","journal-title":"Gastroenterology"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"W J Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"23","key":"ref20","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"P Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"ref21","first-page":"63","article-title":"Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-\u03b1 antagonists","volume":"11","author":"R Fausel","year":"2015","journal-title":"Ther Clin Risk Manag"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"R Panaccione","year":"2014","journal-title":"Gastroenterology"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1097\/MIB.0000000000000092","article-title":"Anti-TNF\u03b1 therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"N Narula","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1741-7015-11-174","article-title":"Safety of TNF-\u03b1 inhibitors during IBD pregnancy: a systematic review","volume":"11","author":"O H Nielsen","year":"2013","journal-title":"BMC Med"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/ecco-jcc\/jjx117","article-title":"The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug[s] for our patients?","volume":"12","author":"P Hindryckx","year":"2018","journal-title":"J Crohn's Colitis"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/ajg.2011.283","article-title":"Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease","volume":"106","author":"L J Herrinton","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"08","key":"ref27","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis","volume":"7","author":"C A Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41395-018-0098-4","article-title":"Lymphoma risk and overall safety profile of adalimumab in patients with Crohn's disease with up to 6 years of follow-up in the pyramid registry","volume":"113","author":"G D\u02bcHaens","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"23","key":"ref29","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"N Nyboe Andersen","year":"2014","journal-title":"JAMA"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease","volume":"158","author":"A Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"issue":"05","key":"ref31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study","volume":"4","author":"N A Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cgh.2012.06.032","article-title":"Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease","volume":"10","author":"I Ord\u00e1s","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","volume":"11","author":"S Ben-Horin","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cgh.2014.12.026","article-title":"Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy","volume":"13","author":"A J Yarur","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"05","key":"ref35","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"J F Colombel","year":"2017","journal-title":"Gut"},{"issue":"08","key":"ref36","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"B G Feagan","year":"2013","journal-title":"N Engl J Med"},{"issue":"07","key":"ref37","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.cgh.2020.07.012","article-title":"Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab","volume":"19","author":"A Hu","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"S 01","key":"ref38","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"G E Fragoulis","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"04","key":"ref39","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"S R Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/apt.14422","article-title":"Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis","volume":"47","author":"S Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"18","key":"ref41","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"W J Sandborn","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"ref42","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","article-title":"Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience","volume":"14","author":"S Honap","year":"2020","journal-title":"J Crohn's Colitis"},{"issue":"07","key":"ref43","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/ecco-jcc\/jjaa249","article-title":"Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING trial","volume":"15","author":"S Vermeire","year":"2021","journal-title":"J Crohn's Colitis"},{"issue":"08","key":"ref44","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"W J Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"S 01","key":"ref45","doi-asserted-by":"crossref","first-page":"S021","DOI":"10.1093\/ecco-jcc\/jjab075.022","article-title":"OP23 efficacy and safety of upadacitinib as induction therapy in patients with moderately to severely active ulcerative colitis: results from phase 3 U-ACCOMPLISH study","volume":"15","author":"S Vermeire","year":"2021","journal-title":"J Crohn's Colitis"},{"issue":"13","key":"ref46","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"B E Sands","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"ref47","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"W J Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/gut.4.4.299","article-title":"The course and prognosis of ulcerative colitis","volume":"4","author":"F CTS Edwards","year":"1963","journal-title":"Gut"},{"issue":"04","key":"ref49","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","article-title":"The pattern and outcome of acute severe coliti","volume":"4","author":"L Walsh AJ Dinesen","year":"2010","journal-title":"J Crohn's Colitis"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/bmj.2.4884.375","article-title":"Cortisone in ulcerative colitis; preliminary report on a therapeutic trial","volume":"2","author":"S CWL Truelove","year":"1954","journal-title":"Br Med J"},{"issue":"05","key":"ref51","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"J DIK Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"issue":"07","key":"ref52","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study","volume":"128","author":"G J\u00e4rnerot","year":"2005","journal-title":"Gastroenterology"},{"issue":"06","key":"ref53","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1572-0241.1999.01149.x","article-title":"Intravenous cyclosporin in ulcerative colitis: a five-year experience","volume":"94","author":"R D Cohen","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"03","key":"ref54","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.cgh.2018.04.060","article-title":"Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease","volume":"17","author":"B Christensen","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"ref55","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study","volume":"19","author":"J A Berinstein","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"03","key":"ref56","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1572-0241.2007.01653.x","article-title":"Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis","volume":"103","author":"W Cacheux","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"02","key":"ref57","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.cgh.2014.09.045","article-title":"Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis?","volume":"13","author":"H H Herfarth","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"06","key":"ref58","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/gut.38.6.905","article-title":"Predicting outcome in severe ulcerative colitis","volume":"38","author":"S PFJ Travis","year":"1996","journal-title":"Gut"},{"issue":"02","key":"ref59","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s10620-019-05668-6","article-title":"Acute severe ulcerative colitis: the Oxford criteria no longer predict in-hospital colectomy rates","volume":"65","author":"A C Moore","year":"2020","journal-title":"Dig Dis Sci"},{"issue":"10","key":"ref60","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1365-2036.2004.01945.x","article-title":"Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery","volume":"19","author":"G TMC Ho","year":"2004","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinics in Colon and Rectal Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1758048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:18:34Z","timestamp":1672273114000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1758048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":60,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2022,12,28]]},"published-print":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1758048","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1531-0043","1530-9681"],"issn-type":[{"value":"1531-0043","type":"print"},{"value":"1530-9681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}